Teva and Fosun Pharma Partner to Advance Anti-PD1-IL2 Therapy for Cancer Treatment
Tuesday, June 17, 2025
Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical Group have formed a strategic partnership to support the development of TEV-56278, an investigational anti-PD1-IL2 ATTENUKINE therapy aimed at treating various forms of cancer.
TEV-56278 is a novel fusion protein that combines a PD-1-targeting antibody with interleukin-2 (IL-2), delivered through Teva’s ATTENUKINE technology. It is designed to direct IL-2 specifically to PD-1-positive T cells in the tumour environment. This targeted mechanism aims to enhance T-cell response against cancer cells while reducing toxicity to healthy tissues.
The collaboration brings together Teva’s innovative ATTENUKINE technology and Fosun Pharma’s expertise in oncology and commercial capabilities across key Asian markets.
As part of the agreement, Fosun Pharma will have exclusive rights to develop, manufacture, and commercialise TEV-56278 across mainland China, Hong Kong SAR, Macau SAR, Taiwan, and selected Southeast Asian countries. Teva will retain the rights to the therapy in all other regions. The partnership is expected to accelerate the generation of clinical data, which Teva may utilise to support development efforts in additional geographies.
Preclinical studies have shown promising results, including tumour regression, increased T-cell infiltration, and sustained immune response. TEV-56278 is currently being evaluated both as a standalone treatment and in combination with pembrolizumab, a well-known immunotherapy.
This collaboration marks a significant step in Teva’s pipeline development and is intended to speed up access to innovative treatments for patients across global markets.
Source: tevapharm.com
